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Abstract 
Despite the adverse effects of microbial hazards on public health, major pharmaceutical firms 
have left the field of anti-infective development and a dramatic reduction in the number of 
researcher’sintricated in the quest for new specific anti-infective leads. In the non-existence of an 
efficient forum for antibiotics development and over usage in human beings and animals, 
bacteria have demoralized this potential by gradually establishing the resistance toward most of 
the antibiotics used. Thus, the production of novel and successful anti-infectivedrugs is urgently 
required to combat this resistance. Hydrazones and hydrazides have mounted as a key-skeleton 
for the development of active drugs, due to their important biological and pharmacological 
profiles.Hydrazones are being manufactured as medicines by various investigators to fight 
against the ailments with maximal effects and minimal toxicity.This paper focuses on the outline 
of the literature results of recent years, incorporating the work on the anti-infective profileof 
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hydrazoneanalogues. This review may also act as an excellent basisfor the development of new 
derivatives of hydrazone as potential anti-infective mediators. 
Keywords: Hydrazones, anti-infective, antiviral, antitubercular, biological activity, structure-
activity relationship. 
Highlights:  
1) This review highlights the potential of hydrazone derivatives as the development of newer 
pharmacologically active anti-infective agents. 
2) SAR study of hydrazone based analogues and concise description of nanocarriers as efficient 
anti-infective agents. 
3) A wide range of analogues has potent anti-infective activity against various bacterial, fungal 
and viral strains. 
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Hydrazone ligands have attracted particular attention from researchers due to their well-known 
chelating capability, structural versatility and diverse range of applications. The metal complexes 
of hydrazones are including heterocyclic moieties containing nitrogen, oxygen and sulphur as 
hetero-atomshave been studiedextensively to create a probable relationship between the chemical 
structure and biological activity. Among them, Schiff's base hydrazones bearing nitrogen-
containing moiety have attracted considerable attention due to their impressive chemical and 
physical properties, biological activities and also their analytical applications [1]. They are 
considered as the major category for the development of new drugs, determination of innovative 
biologically active molecules against multidrug-resistant microbial infections and can act as 
multidentate ligands with transition metals which demonstrate many therapeutic applications [2]. 
Hydrazone characterizes as a resourceful compound having a basic structure R1R2C=NNR3R4. 
Azomethine is a very important group of Schiff’s bases,in which C=N is used as interesting 
ligand in coordination chemistry [3-5]. Hydrazone-type compounds containing an azomethine 
constitute an important class of compounds for the production of new drugs. The hydrazone 
community is well known to play a significant role in antiinfective profile [6]. Hydrazones are 
related to the ketones and aldehydes. Theyare formed by substituting the oxygen group of 
carbonyl compounds with the functional group -NNH2. They act as reactants in several important 
reactions such ashydrazone iodination, Shapiro reaction and Bamford-Stevens reaction to form 
vinyl compounds. Also,theyact as an intermediate in Wolff-kishner reduction [7]. Hydrazones 
are mainly synthesized by refluxing the appropriate quantity of substituted hydrazines/hydrazides 
with ketones and aldehydes in appropriate solvents like tetrahydrofuran, glacial acetic acid, 
methanol, ethanol, butanol, ethanol-glacial acetic acid etc.Coupling of aryldiazonium salts with 
active hydrogen compounds can also synthesize hydrazones [8]. Hydrazides and hydrazones are 
not only intermediates but, in their own right, they are also very effective organic compounds 
[9]. They contain nitrogen atoms which have nucleophilic and the carbon atom has both 
nucleophilic and electrophilic effect. The hydrazones endowed with α‑ hydrogen are more 
potent as compared to acidic ketones. Schiff’s bases produced by salicylaldehyde and its 
analogues with primary amines, bearing the N2O, NO2, N2S or NSO donor sets, possess 
scrupulous biological activities [10-12]. They were commonly used in the identification and 
quantitative determination of various metallic compounds, analytical chemistry for the detection 
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and isolation of carbonyl compounds, for preparation of compounds with different structures. 
However, their greater physiological activity is the most important property of hydrazone 
derivatives [13]. Nowadays, emerging bacterial resistance is the chiefdifficulty in the handling of 
several infections, with the intention of that many hydrazone compounds have been prepared and 
examined for their anti-infective activity [14-15].  
Recently, metal complexes of Schiff's bases have been fascinated the considerable interest dueto 
their versatile pharmacological activitiesaredescribed in Fig. 1. such as anti-cancer [16-17], 
antiviral [18-19], anti-TB [20-21], antimicrobial [22-23], anti-inflammatory [24-25], 
anticonvulsant [26-27], antiprotozoal [28-29], anti-HIV [30-31], anti-oxidant [32] and analgesic 
[33-34]. Few marketed drugs bearing hydrazone nucleus related to various biological activities 
are mentioned in Fig. 6. 
 
Fig.1.Various pharmacological activities of hydrazone derivatives. 
Nanotechnology generally refers to an area of applied science and technology whose general 
theme is atomic and molecular control of matter [35]. Nanotechnology in medicine, particularly 
in drug delivery is already widely used and discussed in many medical fields. Not only the drug 
can be distributed proficiently to the site of infection with the aid of nanomaterials but even the 
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quantity and intensity of dosage can be regulated by avoiding therapy-related toxicity [36]. 
Nanoparticles are materials with at least one dimension (1-100 nm) within the range of the 
nanometer scale or whose basic unit is within this range in three-dimensional space(various 
applications, types and properties of nanoparticles are shown in Fig. 2).  
 
Fig. 2. Applications, types and properties of nanoparticles [37,38]. 
In particular, nanoparticles have a wide range of antibacterial properties towards Gram-positive 
and Gram-negative bacteria [39]. Because of its high surface area to volume ratio and specific 
physical and chemical properties, inorganic compounds in nanosize show significant antibacterial 
activity at low concentrations [40]. The bactericidal activity of these nanocarriers depends greatly 
on stability, the concentration of the growth medium and size [41]. When immersed in the 
biological cultural medium, nanocarriers experience various biological interfaces due to the 
presence of cellular molecules such as proteins, DNA, lipids, polysaccharides and flavonoids etc 
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[42]. Mechanism of action of nanoparticles based hydrazonesas antibacterial agents is depicted in 
Fig. 3. Viruses presents a rather significant threat to the medical, pharmaceutical and 
biotechnological fields as a key factor of sickness and mortality of humans. The extraordinary 
capacity of viruses to change easily at the new host and transitioning to a different host is really 
troubling and big recovery shortage. Nanotechnology provides a platform that modify or develop 
the drugs into nanoparticles for the treatment of various infectious diseases. As nanomedicines 
has smaller size they have ability to interact easily with the viruses or other microbes [43]. 
Mechanism of action of nanoparticles based hydrazone compounds as antiviral agents is depicted 
in Fig. 4. A millions of people are affected by tuberculosis and it is the second leading cause of 
death from infectious diseases after AIDS. Nanotechnology offers a a new and effective strategy 
to develop antimycobacterial formulations [44]. The mechanism of action of nanoparticles based 








Fig. 4. Mechanism of action of nanoparticles based hydrazones compounds as antiviral agents 
[47,48]. 
 
Fig. 5. Mechanism of action of nanoparticles based hydrazone 





Fig. 6.Commonly prescribed marketed drugs bearing hydrazone nucleus [51-54]. 
 
2. STRUCTURE ACTIVITY RELATIONSHIP STUDYOF HYDRAZONES 
The structure-activity relationship is the relationship among the 3D-structure or chemical 
structure of a molecule and its pharmacological activity. The SAR analysis allows determining 
the chemical groups accountable for triggering a biological target influence in the organism. 
Medicinal chemists utilize chemical synthesis methodologies to introduce new chemical groups 
into medicinal compounds and check its modification for their pharmacological impacts [55]. 
Hydrazone nucleus comprises N-NH2 functional group, the substitution of R1 with phenyl ring 
containing bromine, 3-methoxy-4-hydroxy groups showed superior antimicrobial activity in most 
of the analogues [56]. In some derivatives, if R1is substituted with 5-nitrofuran-2-yl compounds 
showed better antibacterial activity [57]. Substitution of R1 with electron-accepting groups like 
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F, Cl, Br and NO2 groups displayed strong antifungal activity while analogues with heterocyclic 
moieties like thiophene and indole demonstrated good antimicrobial activity [58]. The most 
potent antitubercular activity was observed when R1 is substituted with chlorine, bromine and 
nitro groups [59]. It was also found that if R2 is substituted with benzothiazole it exhibited higher 
antimicrobial as well as iron-chelating activity [60]. Another substitution of R2 with thiazole-4-
(p-halophenyl) increases antibacterial activity [61]. When R1 was substituted with hydroxyl and 
methoxy group compound showed superior antimicrobial activity [62]. Electron donating 
substituents on phenyl ring at R2 displayed moderate resistance toward microbes [63].The SAR 
of hydrazones as anti-infective agents is detailed inFig. 7. 
 
Fig. 7.SAR of the anti-infective potential of hydrazone derivatives. 
3. SYNTHESIS VIA CONVENTIONAL AND GREEN CHEMISTRY 
Over the decades the conventional chemical synthesis utilizes the hazardous and toxic chemicals 
and solvents in the manufacturing of by-products. This is an intentional implementation of 
chemical reactions to produce one or more products. To overcome all these unfavourable issues 
green chemistry came into consideration with an innovative approach for the synthetic chemist to 
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obtain the product with maximum yield as eco-friendly. The green chemistry approaches were 
observed as the best economic way to obtain a maximum number of synthetic molecules in 
desirable concentration. This chemical synthesis explores our potential challenges in dealing 
with chemical processes and products by introducing new reactions that can optimize the desired 
products and reduce by-products, developing new synthetic schemes and instruments that can 
improve chemical synthesis and searching green solvents that are eco-friendly. Microwave-
assisted synthesis (MAOS) is considered as a synthetic technique through which the laboratory 
chemist can improve processes within a reasonable amount of time compared with traditional 
conductive synthetic methods .Few examples of chemical and green chemistry-based synthetic 
routes of hydrazone derivatives are described in Fig. 8. 
In 2015, Velezheva et al have prepared a novel hybrid series of hydrazides and hydrazide-
hydrazones possessing the pyrimidine and indole moiety by following Scheme 1[64].In 2017, 
Popioleket al have reported a novel sequence of hydrazide-hydrazones of isonicotinic acid. The 
synthetic scheme used by authors is given in Scheme 2[57]. In 2017, Zhaet al have reported a 
new series of benzo-[d]-thiazole-hydrazone derivatives by using the Scheme 3 [58].In 2016, A 
novel series of N´-substituted-4-methyl benzene sulfonohydrazide derivatives were explored by 
Ghiyaet al by using Scheme 4 [59]. In 2016, A novel class of small molecules of benzothiazole- 
hydrazones were investigated by Sarkar et al using Scheme 5 [60].In 2016, Gomathiet al have 
synthesized a novel class of hydrazone schiff’s bases. Different hydrazone schiff’s bases were 
prepared by using the following Scheme 6 [65].In 2017, Fadareet al have investigated a new 
class of monocarbonyl curcumin analogues and their 2, 4-dinitrophenyl hydrazones using 
Scheme 7 [66]. In 2012, Torjeet al have reported a novel sequence of Phenothiazine-
carboxaldehyde-hydrazones and bis-hydrazones through Scheme 8, 13[67]. In 2014, Yang et al 
presented a series of novel fluoro-substituted coumarin hydrazones via Scheme 9[68]. In 2015, 
A novel series of mesogenic substituted aroylhydrazones were explored by Singh et al through 
Scheme 10[69]. In 2003, Al-Zaydi et al described a new series of 2-arylhydrazonopropanals 
using Scheme 11 [70]. In 2010, A new series of highly functionalized 4-methyl-1H-quinolin-2-
ones were identified by Siddiqui et al via Scheme 12[71]. In 2011, Aboul-Fadlet al identified a 




Fig. 8. The graphical representation of some green chemistry-based synthetic routes of 
hydrazone analogues. 
 
4. LITERATURE SURVEY OF HYDRAZONES 
4.1 Antimicrobial Activity 
Kamal et al (2019), reported a novel class of 2-arylidene-1-(4-methyl-6-phenylpyrimidine-2-yl) 
hydrazine analogues and their antimicrobial activity was tested against two Gram-positive 
bacterial strains (B. subtilis MTCC-121 and S. aureus MTCC-96) and two Gram-
negativebacterial strains (E. coli MTCC-1652 and P. aeruginosa MTCC-741). Most of the 
synthesized compounds displayed promising antimicrobial activity against both Gram-positive 
bacterial strains. The result showed that the compound 1 displayed the potent antimicrobial 
activity againstB. subtilisand S. aureus with significant MICvalues of 50 μg/mland 100 µg/ml, 
respectively and the compounds 2, 3 and 4showed good activity against S. cerevisiae having a 




Rezki et al (2019), reported a novel series of pyridinium hydrazones and phenoxy conjugates. 
Their antibacterial activity was testedagainst two strains of Gram-positive bacteria,Clostridium 
difficile and MRSA (Methicillin-Resistant Staphylococcus aureus) and two strains of Gram-
negative bacteria, Escherichia coli and Neisseria gonorrhea and their antifungal activity was 
tested against Candida albicans. The result showed that the compound5 against MRSA, E.C with 
(MIC=32, 64 μg/ml) and compound 6 (MIC=16 μg/ml) toward MRSA displayed potent 
antibacterial and antifungal activity [74]. 
 
Khattab et al (2019), investigated a series of novel hydrazone dyestuff’s and screened towards 
E. coli,S. aureus and C. albicans for their antimicrobial activity. It was determined 
thatanalogue7displayed the effective antibacterial activity, possessing the bacterial reduction of 
10±1.4%against S. aureus and 9±1.3% against E. coli and antifungal activity towards C. 
albicans, which suggested that these dyes may be used in future for thetreatment of the bacterial 
and fungal infection [63]. 
 
Popiolek et al (2018), reported a series of novel 2,3-dihalogen-substituted propionic acid 
hydrazides and hydrazide-hydrazones and screened for their in-vitro antimicrobial activity 
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towards Gram-positive strains (S. aureus ATCC-25923, S. aureus ATCC-43300, S. aureus 
ATCC-6538, B. subtilis ATCC-6633, B. cereus ATCC-10876, S. M. luteus ATCC-10240, 
epidermidis ATCC-12228) and Gram-negativestrains (B. bronchiseptica ATCC-4617, E. coli 
ATCC-25922, P. aeruginosa ATCC-9027, S. typhimurium ATCC-14028, K. pneumoniae 
ATCC-13883, P. mirabilis ATCC-12453) and antifungal activity against yeast (C. albicans 
ATCC-10231C. andParapsilosis ATCC-22019).Amongst them,the compound 8 with MICvalue 
of 62.5 µg/ml showedcomparable activity as compared toampicillin with MIC value of 62.5 
µg/ml and the compound 9displayed strong antibacterial activity in response to all bacterial 
strains,having MIC values in ranges between 31.25-125 µg/ml and MBCvalues from 62.5-250 
µg/ml [57]. 
 
Abdelrahman et al (2017), reported two novel series ofnicotinic acid hydrazones and quinolone 
hydrazide analogues. They were tested for their in-vitro antimicrobial activity. Results showed 
that the compounds 10 and 11 bearing 3,4,5-trimethoxy and 2,5-dimethoxy benzylidene moieties 
were found to be exhibited the excellent antibacterial and antifungal activity, having significant 
MIC values in the range between 0.49 to 1.95 and 0.49 to 0.98 µg/ml, respectively. Also, several 
derivatives (12-23) displayed significant antimicrobial activities with MIC values in the 





Ajani et al (2017), introduced a new series of quinoline based 4-hydrazide hydrazoneanalogues 
and examined them for their antibacterial activity towards six bacterial species such as E. coli,S. 
aureus, B. lichenformis, M. varians, P. aeruginosa and P. vulgaris. Maximum of the analogues 
exhibitedthe highest antibacterial activity. It was concluded that compound 24 displayed the 
most potent antibacterial activity towards all bacterial strains having MIC valuesin the range 
between 1.59-0.39 µg/ml [75]. 
 
Cordeiro et al (2016), described some isoniazid-derived hydrazone analogues and tested for 
their in-vitro antifungal activity towards Coccidioides posadasii. Most of the synthesized 
derivativesexhibited good antifungal activity but the compound 25 showed the most potent 
antifungal activity towards Coccidioides posadasii strain with MIC value of 100-400 µg/ml. 
Thus, the results of the present identification revealed that in future, compound 25 may be used 
against fungal infections [76]. 
 
Kethireddy et al (2015), reported a novel series of 5, 6, 7, 8-tetrahydroimidazo [1, 2-a] 
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pyrimidine-2-carbohydrazide and evaluated for their antibacterial activity towards several 
bacterial strains. It was revealed that the analogues26, 27 and 28 displayed the maximum 
antibacterial activityagainst two bacterial strains Gram-positive bacteria (S. aureus) and Gram-
negative bacteria (E. coli) with a zone of inhibition 30-33 mm [77]. 
 
Kaplancıklı et al (2014), investigated some novel pyrimidine hydrazone derivatives and 
evaluated them against several species including, E. coli, B. cereus, P.aeruginosa, B. subtilis, 
S.typhimurium,S. marcescens, S. epidermidis and C.utilis for their antimicrobial activity. All the 
synthesized derivatives displayed potent antimicrobial activity. It was detected that analogue 29 
exhibited a strong antimicrobial activity towards all the evaluated species with MIC values in the 
range between 31.25-250 µg/ml [78]. 
 
Singh et al (2013), explored a novelsequence of phenyl hydrazonescontainingpyrimidine and 
pyrazolederivatives and tested for their antibacterial activity. Maximum of the prepared 
derivatives displayed potent antibacterial activity. Among them, compound 30 showed the most 
promising antibacterial activity towards B. cereus and B. subtilis with MIC values of 6.25 µg/ml 




Sridhar et al (2013), scrutinized a novel series of (E)-N'-(substituted-benzylidene)-2-(7-fluoro-
2-methoxyquinolin-8-yl) acetohydrazide-hydrazone analogues and examined them for their 
antibacterial activity toward several bacterial strains including, E. coli (MTCC-443), S. aureus 
(MTCC-96), S. pyogenes (MTCC-442) and P. aeruginosa (MTCC-424). Most of the compounds 
displayed anexcellent antibacterial activity. Among them, compounds 31 and 32 exhibited the 
strong antibacterial activity from 18-21 mm with the inhibition region. SAR study of analogues 
revealed that the existence of 2, 4-difluoro and 3, 4-difluoro moiety exhibited the maximum 
antibacterial activity [80]. 
 
Govindaswami et al (2011), illustrated some novel vanillin related hydrazone derivatives and 
screened them towards two bacterial strains Gram-positive bacteria (S. aureus) and Gram-
negative bacteria (P. aeruginosa) for their antibacterial activity. Most of these derivatives 
showed moderate antibacterial activity as compared to the marketable compounds. Among them, 
the compound 33 was found to be most potent towards S. aureus (6-8 mm) and compound 34 




Asati et al (2011), reported a series of novel1,3-benzothiazole-2-yl-hydrazone analogues and 
tested for their antibacterial activity towards several bacterial strains (E. coli, B. subtilis,P. 
alkaligenes, K. pneumoniae) and antifungal activity towardsfungal strains (A.niger, R.oryzae and 
C. albicans). Results indicated that compounds 35 and 36 displayed the excellent antibacterial 
and antifungal activity towards all strains of bacteria and fungus with a zone of inhibition of 18-
23 mm [82]. 
 
Ajani et al (2010), developed a new class of 2-quinoxalinone-3-hydrazone analogues by using 
the technique of microwave irradiation. They were evaluatedfor their antimicrobial activity 
whichshowed that this molecular context displayed the noticeableeffectiveness as antimicrobial 
agents. The result indicated that the analogue 37 exhibited utmost promising antibacterial 




Deep et al (2010), invented a sequence of new biphenyl-4-carboxylic acid hydrazide-
hydrazoneanalogues and characterized them by using analytical and spectral methods. They were 
evaluated for their in-vitro antimicrobial activitytowards two strains of Gram-positive bacteria(B. 
subtilis and S. aureus) and two strains of Gram-negative bacteria (P. aeruginosa and E. coli) and 
two fungal strains (A. niger andC. albicans). Most of the analogues displayed effective 
antimicrobial activity.The result showed that compound 39 exhibited the most potent 
antibacterial activity, having lower antifungal action and compound 40 exhibited the most potent 
antifungal activity, having lower antibacterial action [84].  
 
Khan et al (2009), described and investigated some novel hydrazone derivatives of 
quinoxalinone and characterized them by FT-IR and 1H-NMR data. Their in-vitro antimicrobial 
activity was evaluated towardstwo bacterial strains Gram-positive bacteria (S. aureus ATCC-
29213) and Gram-negative bacteria(E. coli ATCC-25922).It was revealed that compounds 41, 
42, 43 and 44 exhibited the comparatively good activity towards both types of bacterial strains, 
using ofloxacin as the reference drug. Also, this study showed that the compounds containing 
extremely electronegative substituents (chloro and fluoro) at the para-position of phenyl ring 
displayed better activity in comparison to the analogues containing these atoms either at ortho or 
meta-positions or the other analogues comprisingfewer electronegative/electropositive 





  4.2 Antiviral Activity 
            In the early 20th century, infectious diseases were the most common cause of human illness 
leading to the death [86]. Malignant tumors and viral infections represent the world's most 
significant threats to public health [87]. Based on current scenario, the spread of Corona Virus 
Disease (COVID-19) has become a major global public health event, threatens to people's 
physical and mental health and even life protection, affecting all age groups with a higher 
incidence in geriatric populations and chronic diseases [88,89]. Severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) is a strain of corona virus that causes coronavirus 
disease (COVID-19). In these days, spread of SARS-CoV-2 virus through air has become a 
controversial subject among scientists. Various organizations provide standard methods for 
monitoring the biological agents [90]. 
Recently available most of the therapeutically active antiviral medications are intended against 
human immune deficiency virus (HIV), herpes viruses (best known for causing the cold sores 
and genital herpes, but causing a wide variety  of diseases), hepatitis B and C viruses and 
influenza A and B viruses [91]. However, prolonged treatment with antiretroviral therapy results 
in the disease progression. Nowadays, a great advancement requires in the production of newer 
drugs which may serves as targeted essential aspects of the HIV life cycle in the field of research 
and development. This includes viral entry (fusion inhibitors) and penetration into the host 
genome (integrase inhibitors).There is an increasing demand of New Chemical Entities (NCE’s) 
and drug substances due to the increased resistance, recurrence and spread of various diseases, 
growing number of immunocompromised patients and emergence of many new infections. These 
have made it possible to identify new medications that are useful in clinical therapy in order to 
face good health conflict [92]. A large number of hydrazone derivatives have been synthesized 
and studied for the wide range of antiviral activity. 
Yang et al (2018),developed a novel series of pyrazole-hydrazone analogues bearing an 
isoxazole skeleton. They were evaluated for their antiviral activity by using antiviral 
bioassay(half-leaf method)which indicated that few derivatives showed better in vivo antiviral 
activity towards tobacco mosaic virus (TMV). Amongst, compounds 45, 46 and 47 displayed the 
best protection activity, inactivation activity and therapeutic activity against TMV, respectively, 
which were greater thanstandard drug Ningnanmycin. This study confirmed that this series of 
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novel pyrazole-hydrazone analogues containing an isoxazole amide moiety can be considered for 
the further development as a new class of tobacco protection agents [93]. 
 
 
Shah et al (2018), reported a new class of 8-hydroxyquinoline-hydrazone derivatives and 
characterized them by using 1H-NMR, 13C-NMR, HRMS and IR techniques. All the synthesized 
analogues were tested for their anti-HIV-1 activity. Results showed that the compound 48 was 
found to be most potent (IC50: 1.88 and 6.27 μM, TI: 73.82 and 22.07, toward HIV-1VB59 and 
HIV-1UG070, respectively). This compound 48 (4-methoxy substitution on phenyl ring) 
exhibitedthe highest anti-HIV-1 activity (6.5 and 1.6 folds higher) with selectivity (TI 
approximately 12 and 3 times) against both HIV-1 strains as compared to the parent compound. 
Thus, the compound 48 can be considered as a lead for improving its anti-HIV-1 potential [30]. 
 
Singh et al (2013),prepared a novelsequence of phenyl hydrazonecomprisingpyrazole and 
pyrimidine derivatives and evaluated against TZM-bl cells for their anti-HIV activity at the 
concentration of 50 µg ml-1. The result indicated that most of the analogues displayed 
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promisinganti-HIV activity. It was observed that at a test dose, compounds49, 50, 51 and 52 
displayed more than 85% inhibition of HIV while analogue 53 showed 98% inhibition. It was 
demonstrated that these designed molecules have the possibility of introducing the chemical 
diversity around the core skeleton to generate newer potent molecules[79]. 
 
Ma et al (2011), invented a novel sequence of aryl-2-[(4-cyanophenyl)amino]-4-pyrimidinone 
hydrazone derivatives and tested toward human immunodeficiency virus (HIV)-1 in MT-4 cells 
for their antiviral activity. Most of the compounds showed tremendous activity towards wild-
type HIV-1, with EC50 values between 1.7-13.2 nm. Among them, the compounds 54 
(EC50=2.4±0.2nm, SI=18461), 55 (EC50=2.6±1.2 nm, SI=2673) and 56 (EC50=1.7±0.6 nm, 
SI=5762) presented the effective activity as compared to ETV towardstrains of wild-type HIV-1. 
Furthermore, the activity of compounds 54 and 56 against HIV-1 RT(WT), CCR5-tropic HIV, and 
CXCR4-tropic HIV indicates that the target of hyd-CH2-DAPYs is wild-type RT only [94]. 
 
Zhan et al (2010), reported a novel sequence of N´-arylidene-2-[1-(naphthalen-1-yl)-1H-
tetrazol-5-ylthio] acetohydrazide analogues as nonnucleoside reverse transcriptase inhibitors 
(NNRTIs)and screened them using IIIB strain and ROD strain for their in vitro HIV-1 and HIV-2 
activity, respectively. The activity was scrutinized via the retardation of virus persuaded 
cytopathic effects in human T-lymphocyte (MT-4) cells. Results revealed that the analogues 57 
and 58 showed EC50 values of 29.62 µM (CC50 of 169.24 ± 23.83 µM)and 31.62 µM (CC50> 
309.06 µM) and resulting in selectivity index of 6 and >9, respectively. The compounds 
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nevirapine (NVP), efavirenz (EFV), delavirdine (DLV) and zidovudine (azidothymidine, AZT) 
were used as the reference drugs [95]. 
 
El-Sabbagh et al (2009), synthesized a novel series of hydrazone derivatives from cyclic β-
diketone and their structures were characterized by utilising elemental analysis and numerous 
spectroscopic techniques. They were screened toward Hepatitis-A Virus (HAV) for their 
antiviral activity by using the plague infectivity reduction assay method. It was detected that the 
compound 59 demonstrated the tremendous antiviral activity, in comparison to the reference 
drug amantadine [87]. 
 
Vicini et al (2009), explored a novel sequence benzo[d]isothiazolehydrazoneanalogues and 
examined for their anti-HIV activity in MT-4 cells culture toward wild type strains of HIVand 
HIV-1 which carry clinically appropriate genetic variations (EFVR, Y181C and K103/ Y181C). 
It was revealed that in this evaluated series, benzo[d]isothiazol-3(2H)-one moiety was vital for 
anti-HIV activity. Results showed that analogues 60 and 61 displayed decent activity towards 
HIV-1 wild type strains, while the analogues 60, (62-69) exhibited good activity towards EFVR 





4.3 Anti-TB Activity  
Dogan et al (2020), developed a novel series of thiadiazolylhydrazonesand were tested for their 
in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv using Microplate 
Alamar Blue Assay (MABA) method. Most of the compounds showed good antitubercular 
activity in the range of MIC 0.78-6.25 μg/ml. Compounds70and71showed prominent 
antitubercular activity at MIC of 0.78 μg/ml. It is concluded that these compounds possessed 
antitubercular activity due to enoyl acyl carrier protein reductase (InhA) as the possible target 
enzyme [97]. 
 
Sutar et al (2019), prepared a new series of isoniazid-transferrin conjugates viz TF-IH and TF-
IG (72, 73). They were further investigated for their in-vitro anti-tubercular activity. These 
conjugates were found to have higher pH-dependent stability and better anti-TB activity than 
free isoniazid. Transferrin-IH conjugates exhibited a significant drop in the colony-forming unit 
at 0.39 µg/ml conc. than Transferrin-IG & free INH during ex-vivo studies. Hence, it’s evident 
that the conjugation of anti-tuberculosis agents with transferrin improves the potency and 





        
Sampiron et al (2019), presented a novel sequence of hydrazone, benzohydrazones and 
isoniazid-acylhydrazones derivatives and determined for their in vitro antitubercular activity 
against M. tuberculosis H37Rv and other various strains. All compounds revealeddecent activity 
at MIC of 0.12-250 μg/ml. They exhibited significant MIC at both pH 6.8 and 6.0. Compounds 
74-77 with isoniazid-acylhydrazones showed prominent results. Based on the above results, 
isoniazid-acylhydrazones can be used for new drug development as antitubercular agents [99]. 
 
 
Hakkimane et al (2018), reported a novel sequence of rifampicin-loaded poly lactic-co-glycolic 
acid nanoparticles and isoniazid derived isoniazid benz-hydrazones and testedfor theiranti-
tubercular activityagainst the H37Rv strain of Mycobacterium tuberculosis. It was observed that 
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analogue 78 showed potent antimycobacterial activity, better stability and sustain release 
properties for one month. All the synthesized compounds were found to be better anti-TB agents 
and have more efficacy in drug delivery than free forms [100]. 
 
Bonnett et al (2018), explored a series of hydrazones and examined for their antimycobacterial 
activity toward non-replicating M. tuberculosis species. All the parameters like Minimum 
Inhibitory Concentration (MIC), Low Oxygen Recovery Assay (LORA) and Minimum 
Bactericidal Concentration (MBC) were recorded for tested compounds. Most of them showed 
excellent anti-tubercular activity. Amongst, two compounds 79 and 80 exhibited the remarkable 
activity under hypoxic conditions than aerobic culture. In a nutshell, hydrazones have prominent 
activity as antitubercular agents [101]. 
 
Luet al (2017), reported two novel series of benzylsulfanyl benzo-heterocyclic amides and 
hydrazones derivatives. These compounds were assessed for their anti-TB activities and some of 
the isonicotinylhydrazones derivatives possessed decent anti-tubercular activity towards the 
H37Rv strain of M. tuberculosis. MIC values of these compounds were found to be better than 
isoniazid, moxifloxacin, streptomycin and PA-824. Further, in-vivo studies explored that 
compound 81can be used as a new anti-TB agent as it significantly lowers the activity of 




Abdelrahmanet al (2017), have identified a new sequence of pyridine and quinoline based 
hydrazoneanalogues. The prepared analogues were evaluated for their anti-TB activity. Results 
concluded that analogues 82, 83 and 84 displayedremarkableantimycobacterial (MIC = 0.39 
µg/ml). Whereas, the compounds 85, 86, 87 and 88 displayed excellent antimycobacterial 
activity(MIC= 0.78 µg/ml) [62]. 
 
 
Joshi et al (2016), prepared anovel sequence of pyrrolyl hydrazones and their Cu(II) complexes. 
The compounds were analyzed in-vitro for their anti-tubercular activity against the bacterial 
strains of M. tuberculosis. As compare to ligands metal-complexes were found to be more 
potent. Compounds (89-91) showed appreciable anti-TB activity with MIC value of0.8 μg/ml 
against standard drug rifampicin. These compounds were able to bind more than 60% with 




Cihan-Ustundaʇ et al (2015), developed a novel series of indoyl hydrazones and indole-based 4-
thiazolidinones. The synthesized analogues were examined in-vitro for their anti-tubercular 
activity towards Mycobacterium tuberculosis H37Rv. It was found that compounds 92-96 
showed excellent anti-TB activity with a 10-fold lower concentration of mammalian cell toxicity 






Abdel-Azizet al (2015), presented three novel series of halophenyl bis-hydrazones and tested for 
their antimycobacterial activities. Results indicated that analogues 97-101 possessing broad 
antimicrobial activity against Mycobacterium tuberculosis. The above mentioned five analogues 






Dandawate et al (2014), investigated a new sequence of four analogues (102-105) of 
ferrocenylhydrazones under varied iron conditions and their β-cyclodextrin (CD) inclusion 
complexes were synthesized and examined for their anti-tubercular activity. It was discovered 
thatlow MIC values (0.5-128 μg/ml) against 7H9 medium were shown by cyclodextrin inclusion 
complex of INH. FBHZ and its cyclodextrin inclusion complex was found to be the most 
significant amongstthem and exhibited MIC values of 1.0 and 0.5 μg/ml. Cyclodextrin 
conjugates hold good potential for the production of antitubercular drugs under varied iron 
condition [106]. 
 
Jamadaret al (2012),arranged a new sequence of pyruvate based hydrazones and tested toward 
M. tuberculosis using middle brook 7H9 medium. About eight of the pyruvate hydrazones and its 
sodium salts displayed inactivity in their anionic form. On the other side, prominent 
antimycobacterial activity was displayed by their neutral Cu (II) complexes (106-113) under 
elevated iron (8 μg Fe per ml) condition. The complexes [Cu(L1) (H2O)2] – [Cu (L
8) (H2O)2] 




Mahajan et al (2011), introduced a novel series of ferrocene based hydrazonesand evaluated for 
their anti-tuberculosis activity towards Mycobacterium tuberculosis. Among the tested 
analogues,analogue 114 exhibited potent anti-TB activity against M. tuberculosis, having a MIC 
value of 2.5-5 μg/ml. Results revealed that such hybrid analogues provide an efficient approach 
for future pharmacological developments to fight against tuberculosis [21].  
 
Pinheiro et al (2011), explored a series of L-serniylhydrazone derivatives and screened for 
theirin-vitro antitubercular activity towards Mycobacterium tuberculosis H37Rv. Generally,the 
tested analogues were tested for antitubercular activity and showed good activity. The 
compounds 115-120 showed remarkable activity in the range of MIC 25 and 100 μg/ml, and 





Kumar et al (2010), identified a novel series of benzoic acid hydrazonesand their nicotinyl 
derivatives. The synthesized analogues were assayedin-vitro for their anti-tubercular activities 
against Mycobacterium tuberculosis strain. It was revealed that compound 121showed the most 
potent anti-tubercular activity with MIC value of 3.5×10-3 µM [109]. 
 
Bairwa et al (2010), reported the synthesis of a novel sequence ofphenylacrylamide analogues 
substituting cinnamic acid and guanylhydrazonesby employing microwave-assisted synthesis. 
Resazurin-microtitre plate assay (REMA) was used to evaluate the anti-tubercular activity of 
compounds against Mycobacterium tuberculosis. Results demonstrated that compound 122 is of 
particular interest having good safety profile with MIC of 6.48 μM. In future,the compound can 
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The invention of novel chemotherapeutic agents is an essential and challenging task for the 
medicinal chemists and several research programs are directed towards the design and synthesis 
of newer drugs for their chemotherapeutic usage. To discover active analogues towards 
multidrug-resistant microbial infections, hydrazone containing analogues are found as an 
important class for the development of newer anti-infective drugs. Hydrazone ligands attracted 
the special attention of researchers due to their well-known chelating capability, structural 
flexibility and diverse range of pharmaceutical applications. The present review highlights the 
potential of hydrazone derivatives as a guideline for the advancement of anti-infective agents, 
SAR based study of hydrazone analogues with a diverse mechanism of action of nanoparticles 
based hydrazone compounds as potent anti-infective agents have been addressed in effective 
way.Various conventional and green synthesis of hydrazone derivatives and recents patents filed 
or granted on hydrazone compounds as anti-infective agents have also been tabulated. It could be 
observed that with careful designing of known hydrazone derivatives and future work might 
yield more promising lead compounds with better anti-infective activity. 
 
7. FUTURE ASPECTS:  
Hydrazone is indeed one of the primary drug research scaffolds due to its remarkable therapeutic 
properties. In heterocyclic chemistry, the expansion of effective and reliable methods for their 
synthesis and fusion with many other bioactive molecules has ensured that hydrazones have been 
a crucial moiety. Research thresholds will therefore remain crucial to the discovery of bioactive 
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molecules in order to satisfy all the relevant criteria for the expansion of potent antiviral and 
antimicrobial drugs. Current and re-emerging infectious diseases will continue to present 
significant challenges to global health into the 21st century. According to world health 
organization (WHO) study, these are already considered as leading cause of death and affected 
patient health care system across the world. Because of the rising number of infections and 
resistance towards conventional treatments, there is an persistent need to produce some useful 
medications that can counter resistance and side-effects related to anti-infective medications. In 
addition, rational design and production of the novel anti-infective agents that contain this 
scaffold will help to resolve increasing microbial resistance problems and satisfy the need for 
successful antimicrobial therapy to combat multiple deadly microbial infectious diseases. Based 
on the literature survey, we ascertained that the future of medicinal chemistry should focuses on 
the development of newer molecules with innovative approach in order to obtain therapeutically 
active molecules in forthcoming future. The development of such new molecules includes new 
synthetic instruments, synthetic strategies and techniques.  
ACKNOWLEDGEMENT 
The authors PCS and VKT would like to express their sincere thanks to Newton Bhabha Fund 
for providing the foundation to establish this cross-country interdisciplinary research 
collaboration through Researcher Links scheme. 
 
CONFLICT OF INTEREST 
There are no conflicts of interest in this article. 
 
ABBREVIATIONS 
HAV Hepatitis-A Virus IR Infrared 
ATCC American Type Culture Collection NMR Nuclear magnetic resonance 
DNA Deoxyribonucleic Acid SAR Structure-activity relationship 
MRSA Methicillin-resistant Staphyloccous 
aureus 
REMA Resazurin Microtiter Assay Plate 
MAOS Microwave-assisted organic 
synthesis 
MTCC Microbial Type Culture Collection 
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TMV Tobacco mosaic virus MIC Minimum inhibitory concentration 
µM Micromolar MBC Minimum bactericidal 
concentration 




Low Oxygen Recovery Assay 
µg/ml Microgram per millilitre FBHZ Ferrocenylhydrazone 
MABA 
Microplate Alamar Blue Assay      
ROS 
Reactive oxygen species 
HRMS 
High Resolution Mass Spectrometry 
TZM-bl 
Hela cell line 
HIV Human Immunodeficiency Virus 
EC50 
Half maximal effective 
concentration 
SI Standard international INH Isoniazid 
ROD Varicella-Zoster Virus strain   
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